Firma immatics biotechnologies, Autor bei Presse-Blog

Immatics weitet klinisches Studienprogramm für adoptive Zelltherapien auf Europa aus

18. August 2020 Firma immatics biotechnologiesForschung und Entwicklungactengine, aussagen, cancer, ima200, ima202, ima203, immatics, patienten, pei, tcr, tcrs, ucc, upmc, uthealth

Der erste Patient in Deutschland wurde im Rahmen der Immatics‘ ACTengine® IMA202-101 Studie behandelt Die deutsche Zulassungsbehörde, das Paul-Ehrlich-Institut (PEI), hat den Antrag (CTA, Clinical Trial Application) für eine weitere klinische ACTengine®-Studie in Deutschland genehmigt. Die Studie wird Immatics‘ Produktkandidaten Mehr

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs

18. August 2020 Firma immatics biotechnologiesForschung und Entwicklungcancer, forward, ima201, ima202, ima203, immatics, looking, patients, pei, securities, statements, tcr, ucc, uthealth

First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlich-Institute (PEI), granted approval to commence another clinical ACTengine® trial in Germany investigating Immatics’ IMA203 product candidate Three clinical trial sites in Germany have started Mehr

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth

6. August 2020 Firma immatics biotechnologiesForschung und Entwicklungactallo, actengine, cancer, cell, cells, dentistry, griffin, immatics, patients, research, securities, statements, tcr, uthealth, with

. Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory Collaboration ensures continued clinical batch supply for all Mehr

Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ

9. Juli 2020 Firma immatics biotechnologiesForschung und Entwicklungattack, cancer, cell, chambr, clinical, discovery, financial, immatics, immunotherapies, new, patients, securities, statements, tcr, with

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced changes to its Board of Directors in conjunction with its recent listing on NASDAQ. Michael Atieh, Paul Carter, Mehr

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

30. Juni 2020 Firma immatics biotechnologiesKooperationen / Fusionenarya, aryas, cancer, cell, cells, cms, immatics, patients, perceptive, power, securities, statements, svb, tcr, with

Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced Mehr

Immatics Appoints Cedrik Britten as Chief Medical Officer

4. Juni 2020 Firma immatics biotechnologiesAllgemeinbiontech, cancer, cell, clinical, financial, immatics, immunotherapies, immunotherapy, new, patients, research, statements, tcr, therapy, with

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that Cedrik Britten, MD, has been appointed as Chief Medical Officer (CMO) effective June 1, 2020. Trained as a Mehr

Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies

17. März 2020 Firma immatics biotechnologiesForschung und Entwicklungarya, cancer, dievini, hermes, immatics, market, patients, perceptive, prospectus, revenue, statements, svb, tcr, tcrs, with

Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account Leading institutional investors commit $104 million of cash through a common stock private investment in public equity (“PIPE”) led Mehr

Autor: Firma immatics biotechnologies